An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I
Latest Information Update: 01 Oct 2025
At a glance
- Drugs Lepunafusp alfa (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions
- Sponsors JCR Pharmaceuticals
Most Recent Events
- 28 Aug 2025 Status changed from active, no longer recruiting to completed.
- 16 May 2025 Planned End Date changed from 30 Apr 2025 to 31 May 2025.
- 05 Sep 2024 Results presented in the JCR Pharmaceuticals media release.